The antidiuretic hormone vasopressin (AVP) regulates renal salt and water reabsorption along the distal nephron and collecting duct system. These effects are mediated by vasopressin 2 receptors (V 2R) and release of intracellular Gsmediated cAMP to activate epithelial transport proteins. Inactivating mutations in the V 2R gene lead to the X-linked form of nephrogenic diabetes insipidus (NDI), which has chiefly been related with impaired aquaporin 2-mediated water reabsorption in the collecting ducts. Previous work also suggested the AVP-V 2R-mediated activation of Na ϩ -K ϩ -2Cl Ϫ -cotransporters (NKCC2) along the thick ascending limb (TAL) in the context of urine concentration, but its individual contribution to NDI or, more generally, to overall renal function was unclear. We hypothesized that V 2R-mediated effects in TAL essentially determine its reabsorptive function. To test this, we reevaluated V 2R expression. Basolateral membranes of medullary and cortical TAL were clearly stained, whereas cells of the macula densa were unreactive. A dominant-negative, NDI-causing truncated V 2R mutant (Ni3-Glu242stop) was then introduced into the rat genome under control of the Tamm-Horsfall protein promoter to cause a tissuespecific AVP-signaling defect exclusively in TAL. Resulting Ni3-V 2R transgenic rats revealed decreased basolateral but increased intracellular V 2R signal in TAL epithelia, suggesting impaired trafficking of the receptor. Rats displayed significant baseline polyuria, failure to concentrate the urine in response to water deprivation, and hypercalciuria. NKCC2 abundance, phosphorylation, and surface expression were markedly decreased. In summary, these data indicate that suppression of AVP-V 2R signaling in TAL causes major impairment in renal fluid and electrolyte handling. Our results may have clinical implications.
THE ANTIDIURETIC HORMONE, 8-arginine vasopressin (AVP), is critical for the water-and electrolyte homeostasis in mammals (6) . Its antidiuretic action is chiefly mediated by V 2 vasopressin receptors (V 2 R) expressed along the distal nephron and collecting duct (33, 35, 37) . Binding of AVP to V 2 R leads to activation of major distal ion and water transport proteins via intracellular, G s -mediated cAMP release and stimulation of protein kinase A (PKA) and other kinases (2, 13, 14, 27) . One of the best characterized effects of V 2 R activation is the luminal insertion of aquaporin 2 (AQP2) in the collecting duct principal cells to allow passive water movement from the lumen to the interstitium (6, 14, 32) . Active salt uptake along the water-impermeable thick ascending limb (TAL) of the loop of Henle serves to maintain the longitudinal osmotic gradient and is a prerequisite for efficient water reabsorption from the collecting duct (27, 45) . The furosemide-sensitive apical Na ϩ -K ϩ -2Cl Ϫ -cotransporter type 2 (NKCC2) of TAL is subject to activation by AVP as well (2, 22, 24) . Stimulation of the AVP-V 2 R axis in TAL may promote luminal trafficking, as well as phosphorylation of NKCC2 at several conserved, NH 2 -terminal threonine and serine residues to trigger its activity (15, 21, 33, 41) .
Loss-of-function mutations in the gene encoding V 2 R may cause X-linked nephrogenic diabetes insipidus (NDI), a rare, recessively inherited renal disorder with pronounced polyuria and polydipsia (8) . Functional characterization of several NDIcausing V 2 R mutants has demonstrated alterations in trafficking of V 2 R to the cell surface, binding of AVP to the receptor, and activation of the G s /adenylyl cyclase pathway; appropriate cell culture, or genetically altered mouse models have been developed, and the principal impact of impaired water reabsorption along the collecting duct has been established in this context (8, 55, 57) . Strategies have been proposed to bypass the defective V 2 R signaling with particular emphasis on the altered collecting duct function (9, 29, 31) , but the pathophysiological impact of a compromised V 2 R function in TAL has remained unclear in the context of NDI, as well as in general physiology (6, 8) .
In this study, we have, therefore, addressed the effects of impaired V 2 R signaling in TAL on the urine concentrating mechanism. To this end, we have chosen a targeted, tissuespecific transgenic rat approach using a gene construct, which contained a truncated Ni3-V 2 R mutant under control by the Tamm-Horsfall protein promoter (52, (55) (56) (57) . This mutant was identified in humans as a nonsense mutation (Glu242stop) known to cause human X-linked NDI (54, 57) . The mutant was chosen for its dominant-negative property when coexpressed with wild-type V 2 R (55, 57) . Rats consequently expressed the Ni3-V 2 R mutant solely in TAL epithelia. The resulting suppression of V 2 R signaling in TAL was associated with impaired function of NKCC2 and diminished capacity to concentrate the urine. Our data have illustrated for the first time the impact of AVP-mediated V 2 R signaling in TAL in vivo in the functional context of the urine concentrating mechanism.
MATERIALS AND METHODS

Generation of Ni3-V2R transgenic rats.
For generation of a truncated rat V2R, the Glu242stop nonsense mutation (GAG¡TAG) (57) was introduced into the rat V 2R sequence by PCR-based, site-directed mutagenesis during amplification of a PCR fragment corresponding to amino acids 1-242 of V2R from rat cDNA using the following forward and reverse primers: 5=-ATCGAATTCCCCATCATGCTC-CTGGTG-3= (EcoRI restriction site is labeled by bold font) and 5=-ATCGGATCCTCTAGGATGGCCCTGG-3= (a novel BamHI restriction site, and the introduced stop codon after Glu242 are labeled by bold font). The resulting truncated V 2R mutant was termed Ni3(NH2-terminal intracellular third loop)-V2R (57) . An ϳ3,000 bp-fragment containing the Tamm-Horsfall protein promoter was amplified from 129/SvJ mouse genomic DNA using the following primers: 5=-ATTCCTCGAGATCCAAGTCTCCTTCAAAAC-3= and 5=-AGGAATCGATTGGTCCAGTCACAAGTAAGTGCC-3= (the introduced XhoI and ClaI restriction sites are labeled by bold font) (52) . Both, Ni3-V 2R and the Tamm-Horsfall protein (THP) promoter were cloned in a modified pBluescript vector containing ␤-globin and SV40 pA introns (39) . The microinjection of the transgenic construct into zygotes and uterine implantation for the genera- . Note that anti-V2R antibody selectively recognizes the V2R-GFP-transfected cells, whereas cells subjected to control transfection with THP-GFP are not stained by the antibody (C and F, merge). Representative immunoblot of wild-type (WT) and V2R-deficient (V2R Ϫ/Ϫ ) kidney extracts using anti-V2R antibody; V2R-specific immunoreactive bands at ϳ40 kDa are detected in WT but not in V2R Ϫ/Ϫ (G, arrowheads). Confocal images of cortical TAL showing basolateral V2R signal in WT (arrows) but not V2R Ϫ/Ϫ mouse kidney sections; macula densa sites are flanked by dashed lines in the glomerulus (Gl; H and I). Confocal images of WT rat kidney sections double-immunofluorescence-stained for V2R (green signal) and Na ϩ ,K ϩ ,Cl Ϫ -cotransporter (NKCC2) (red signal) (J and K). Basolateral V2R signal in NKCC2-positive TAL (J) is abolished after preabsorption of the anti-V2R antibody with 10-fold excess of the peptide used for immunization (K). V2R immunoperoxidase labeling showing positively stained cortical TAL epithelium next to negative macula densa (flanked by bars) and glomerulus (Gl; L), and positive staining of collecting duct principal cells but not intercalated cells (M, arrows). Scale bars: 25 m.
tion of the transgenic rat line on the background of Sprague-Dawley rats were performed according to established protocols (39) .
Animals and tissues. Adult (10 wk old) Sprague-Dawley rats [wild-type (WT); n ϭ 6] and Ni3-V 2R transgenic rats (n ϭ 6) were placed in metabolic cages for 18 h with water and chow ad libitum to evaluate their baseline water and electrolyte handling. To assess their urine-concentrating ability, WT (n ϭ 6) and Ni3-V 2R transgenic rats (n ϭ 6) were kept in metabolic cages during 18 h under water deprivation and chow ad libitum to collect urine samples; blood samples were collected by puncture of the tail vein under short isoflurane anesthesia. Plasma and urine electrolytes and creatinine levels were assessed by routine automated methods. Thereafter, rats were housed in standard cages on water and chow ad libitum for 3 days to restore steady-state condition. Rats were then killed by cervical dislocation upon isoflurane anesthesia; kidneys were removed and processed for biochemical evaluation. For morphological studies, rats were euthanized by in vivo perfusion fixation under pentobarbital sodium anesthesia (0.06 mg/g body wt ip). The kidneys were perfused retrogradely through the abdominal aorta using a Na-cacodylate (0.1 M)/hydroxyethyl starch (HES; 4%) buffer to flush, followed by 3% paraformaldehyde (PFA) in cacodylate/sucrose/HES buffer (300 mosmol/kgH 2O, pH 7.4) to fix for 5 min. The kidneys were then removed and processed for paraffin embedding, cryosectioning, or electron microscopy.
All experiments involving animals were conducted in adherence with APS's Guiding Principles in the Care and Use of Laboratory Animals and approved by local authorities (Berlin LAGESO permission G0285/10).
Generation and characterization of anti-V 2R antibody. A 20-amino acid peptide (NH2-CRPMLAYRHGGGARWNRPVL-COOH) mapping the second intracellular loop of V2R with a high degree of homology between rat, mouse, and human receptors but no homology to V1a or oxytocin receptors was chosen for immunization. The peptide was synthesized with an additional COOH-terminal lysine residue for coupling; the antibody was raised in rabbit and affinitypurified by Pineda Antikörper-Service (Berlin, Germany). The resulting anti-V 2R antibody was applied for immunofluorescence, immunohistochemistry, and immunoblotting in rat, mouse, and human kidney tissues, as well as in cultured rabbit-TAL cells transfected with mouse V 2R. Specificity of the antibody was verified by a preabsorption test using 10-fold excess of the target peptide prior to application of the anti-V2R antibody on kidney sections. Kidney samples from V2R-deficient mice were used to control the immunoblotting and immunofluorescence results produced by the anti-V2R antibody (29) .
Immunofluorescence and immunohistochemistry. Anti-V2R antibody, goat anti-aquaporin 2 antibody (Santa Cruz Biotechnology, Dallas, TX), guinea pig anti-NKCC2 antibody, rabbit anti-NCC antibody, and rabbit anti-cyclooxygenase-2 (COX-2) antibody (Cayman Chemicals, Ann Arbor, MI) served as primary antibodies (33) . Fourmicrometer-thick cryostat sections of rat, mouse, or human kidneys were incubated with 0.5% Triton X-100 in PBS for 30 min for antigen retrieval. Paraffin sections were dewaxed and boiled in citrate buffer (pH 6.0) for 5 min to perform antigen retrieval. Sections were then blocked with 5% BSA in PBS for 30 min and incubated with respective primary antibodies diluted in 5% BSA for 1 h at room temperature, followed by overnight incubation at 4°C. For multiple staining, antibodies were applied sequentially, separated by a washing step. Next, appropriate secondary fluorescent Cy2-, Cy3-, or Cy5-conjugated antibodies (Dianova, Hamburg, Germany) were applied for 2 h for signal generation. Nuclear DNA was blue-stained with DAPI. For histochemical signal generation in bright-field microscopy, horseradish peroxidase-conjugated secondary antibody (Dako, Hamburg, Germany) and diaminobenzidine were used. Sections were washed, coverslipped with PBS-glycerol, and evaluated in a Zeiss confocal microscope (LSM 5 Exciter) or a Leica DMRB microscope equipped with a SPOT 32 camera and MetaView 3.6a software (Visitron Systems, Puchheim, Germany).
Quantification of juxtaglomerular cyclooxygenase-2 levels. Cells of the macula densa and adjacent TAL portions, which revealed COX-2-immunofluorescent staining in paraffin sections, were counted, and the results were normalized to the respective numbers of glomeruli, as described previously (5). Kidneys from 6 Ni3-V 2R transgenic and 6 WT rats were evaluated. At least 4 coronary sections per kidney were quantified.
Immunoblotting. Rat or mouse kidneys were homogenized in buffer containing 250 mM sucrose, 10 mM triethanolamine, and protease inhibitors (Complete; Roche Diagnostics, Indianapolis, IN). Nuclei were removed by centrifugation (1,000 g for 10 min), and the supernatants were separated by polyacrylamide gel electrophoresis [50 g protein/lane, as determined by a BCA protein assay reagent kit (Pierce, Rockford, IL); 8% to 10% gels]. After electrophoretic transfer to a polyvinylidene fluoride membrane, blocking was performed using 5% BSA/PBS or 5% milk/PBS, and membranes were incubated with the primary antibodies against V 2R, NKCC2, or phosphorylated NKCC2 (pT96/pT101-NKCC2) for 1 h at room temperature, followed by overnight incubation at 4°C and subsequent exposure to HRPconjugated secondary antibodies for 2 h at room temperature (31) . Immunoreactive bands were detected by chemiluminescence, exposed to X-ray films, and the signals were evaluated densitometrically. All data were normalized for expression of the housekeeping gene ␤-actin detected by monoclonal mouse anti-␤-actin antibody (Sigma).
Real-time PCR. Kidneys from WT and Ni-V 2R transgenic rats were homogenized, and total RNA was prepared using the RNeasy total-RNA-kit (Qiagen, Gaithersburg, MD). Genomic DNA was digested by DNase and cDNA synthesized by reverse transcription of 5 g total RNA using a cDNA synthesis kit (Life Technologies, Carlsbad, CA). Specific TaqMan gene expression assays for NKCC2 and GAPDH were ordered by Applied Biosystems (Foster City, CA). Amplification was performed using the real-time PCR TaqMan Fast 7500 (Applied Biosystems). Samples were incubated 94°C for 10 min, and then 45 cycles of 95°C (3 s) and 60°C (30 s) were run. Threshold cycle (Ct) values were set in the linear phase of exponential amplification. ⌬Ct between values obtained for NKCC2 (GAPDH was used as house-keeping gene) was calculated and compared between the strains.
Ultrastructural analysis. For immunogold evaluation of cellular NKCC2 distribution, perfusion-fixed kidneys were embedded in London Resin White. Ultrathin sections from WT (n ϭ 6) and Ni3-V2R transgenic kidneys (n ϭ 6) were incubated with primary antibody to NKCC2 (33) followed by a 5-or 10-nm nanogold-coupled secondary antibody (GE Healthcare, Freiburg, Germany) and assessed using transmission electron microscopy. Quantification of immunogold signals in TAL profiles was performed on micrographs according to an established protocol (44) . Gold particles were attributed to the apical cell membrane when located near (within 20 nm of distance) or within the bilayer; particles found below 20 nm of distance to the membrane up to a depth of 2 m or until the nuclear envelope were assigned to cytoplasmic localization. At least 10 profiles and 4 or 5 cells per profile were evaluated per individual animal.
Statistics. Results of densitometric evaluation or plasma and urine parameters were evaluated using routine parametric statistics. Groups were compared by means of Student's t-test or, if the data violated normal distribution, the nonparametric Mann-Whitney U-test. A probability level of P Ͻ 0.05 was considered significant. Data are presented as the means Ϯ SD.
RESULTS
Renal distribution of V 2 R. Previous work, including our own data, has defined renal V 2 R mRNA and protein expression along the nephron (18, 33, 35, 37, 47) , but results were, in part, inconclusive owing to insufficient specificity of the anti-V 2 R antibodies employed. Therefore, we aimed to raise a more PCR amplification of the transgenic Ni3-V2R construct using cDNA probes of kidney, liver, and heart from WT and Ni3-V2R transgenic rats; Ni3-V2R is exclusively expressed in transgenic kidneys (A, arrows). Representative immunoblot of WT and Ni3-V2R transgenic rat kidney extracts using anti-V2R antibody shows regular immunoreactive bands between 50 and 75 kDa in both genotypes and an additional immunoreactive product of lower molecular weight in the Ni3-V2R kidneys at ϳ30 kDa. The fast migrating product likely reflects the expression of the truncated mutant (B, arrow). Representative confocal images of kidney sections from WT and Ni3-V2R transgenic rats labeled with the anti-V2R antibody (green signal). Double staining for NKCC2 (red signal/asterisks in C and D) or AQP2 (red signal in E and F) demonstrates the selective enhancement of V2R signal in TAL from Ni3-V2R kidney (D). Anti-V2R antibody concentration was adjusted to below saturation levels in C and D, yielding low signal in WT to allow for adequate visualization of the Ni3-V2R transgenic effect, whereas higher antibody concentration was used for comparison of V2R levels in collecting duct cells (E and F). Scale bars: 25 m.
specific anti-V 2 R antibody to newly explore the segmental and cellular distribution of the receptor protein in the kidney. The epitope for immunization was selected for absence of homology to the vasopressin V 1a receptor (V 1a R) to exclude crossreactivity of the antibody between receptor subtypes. Specificity of the generated antibody was tested in cultured rabbit TAL cells transiently transfected with green fluorescent protein (GFP)-tagged mouse V 2 R. Nontransfected cells showed no significant immunoreactivity, which may reflect low endogenous expression of V 2 R in these cells or low cross-reactivity of our antibody with the rabbit V 2 R. In contrast, transfected cells identified by the GFP fluorescence were efficiently recognized by the anti-V 2 R antibody (Fig. 1, A-C) . The signal was absent in cells subjected to control transfection with GFP-tagged Tamm-Horsfall protein (Fig. 1, D-F) . Immunoblotting of kidney lysates from WT mice using the anti-V 2 R antibody yielded two immunoreactive bands at 40 to 50 kDa, which agrees with the reported size of the mature V 2 R form (43); no corresponding immunoreactive signal was detected by immunoblotting of kidney lysates obtained from V 2 R-deficient mice (29) (Fig.  1G) . Accordingly, immunofluorescent V 2 R signal was present in WT but absent in V 2 R-deficient kidneys (Fig. 1, H and I) . Specificity of the anti-V 2 R antibody was additionally verified by preabsorption test using 10-fold excess of the specific immunoreactive peptide (Fig. 1, J and K) . In rat kidney sections, V 2 R immunoreactivity was distributed along medullary and cortical TAL, distal convoluted tubule (DCT), connecting tubule (CNT), and collecting duct (CD) epithelia. As revealed by immunoperoxidase staining, the cortical TAL showed marked staining also in its juxtaglomerular portion, with the exception of the negative macula densa cells (Fig. 1L) .
In the CD, only the principal cells showed basal staining (Fig.  1M) . Confocal microscopy of rat kidney immunofluorescence staining confirmed the solely basolateral distribution of the receptor along the distal nephron and in the CNT/CD principal cells; no significant apical V 2 R immunoreactivity was detected. The segment-specific luminal markers, NKCC2, NCC, and AQP2 were used for identification of TAL, DCT, CNT/CD principal cells, and TAL/DCT segmental transition, respectively (Fig. 2, A-L) . Consequently, in all these segments, there was no overlap between luminal transporter and basolateral V 2 R signals. Comparative analysis of the human kidney revealed similar V 2 R distribution along TAL with substantial basolateral signal in cortical and medullary portions, and macula densa was devoid of signal, as found in the rat (Fig. 3,  A-D) . In the human CD, basal V 2 R signal was weaker than in rats (Fig. 3, A and B) . Generally, no V 2 R signal was encountered in cortical and medullary vasculature, interstitial compo- nents, glomeruli, proximal tubules, or thin limbs of the loop of Henle in either rat or human material (Figs. 2 and 3 ). These localization data agree with the concept that AVP not only enhances water reabsorption in CNT/CD, but also stimulates transcellular NaCl transport in TAL and DCT (6, 27) .
Generation of Ni3-V 2 R transgenic rats.
To analyze the impact of impaired V 2 R signaling in TAL in the context of the urine concentrating mechanism, we next generated a tissuespecific transgenic rat line with targeted suppression of V 2 R function in TAL without concomitant impairment of CNT/CD functions. For this purpose, we expressed a truncated V 2 R mutant (Ni3-V 2 R; Glu242stop) in Sprague-Dawley rats using the THP promoter, whose activity is restricted to the TAL (56) . Previous work has detailed how the Ni3-V 2 R mutant exerts a dominant-negative effect on the expression of the full-length V 2 R (55, 57). Generation of the transgenic rats was performed as detailed in the METHODS. The genotypes of the resulting pups were verified by PCR using genomic tail DNA. Rats of either sex showed normal growth. The kidney-specific expression of the transgenic Ni3-V 2 R construct was confirmed by comparative PCR analysis of cDNA from major organs using specific primers to recognize the transgenic transcript; PCR product of the expected size was amplified only from cDNA of Ni3-V 2 R transgenic but not from WT kidneys or other organs (Fig. 4A) .
Immunoblotting of WT and Ni3-V 2 R kidney lysates using our anti-V 2 R antibody, which recognizes both, the full-length and the truncated V 2 R forms, revealed the presence of a fast migrating immunoreactive product at ϳ30 kDa in the Ni3-V 2 R kidneys in addition to the typical V 2 R-immunoreactive pattern present in both genotypes; this product is, thus, thought to reflect the expression of the truncated Ni3-V 2 R construct (Fig.  4B) . To characterize the segmental expression pattern of Ni3-V 2 R in the transgenic kidneys, we applied double-staining immunohistochemistry and confocal microscopy. Virtually all TAL epithelia of Ni3-V 2 R transgenic rats showed markedly stronger V 2 R signal compared with WT rats, which likely reflected the THP promoter-driven expression of the Ni3-V 2 R mutant receptor (Fig. 4, C and D) . In contrast, CNT or CD principal cells of WT and Ni3-V 2 R transgenic kidneys did not show differences in V 2 R expression intensity (Fig. 4, E and F) . Electron microscopic evaluation of cellular V 2 R distribution in TAL, as revealed by immunoperoxidase staining, demonstrated predominantly basolateral localization of the receptor in WT kidney, whereas diffuse cytoplasmic V 2 R staining in Ni3-V 2 R along with reduced basolateral signal suggested impaired trafficking of the truncated receptor (Fig. 5, A and B) . In aggregate, these results confirm the selective expression of the truncated, dominant-negative Ni3-V 2 R mutant as well as markedly reduced abundance of membrane-associated V 2 R signal in TAL of the transgenic rat kidneys.
Phenotype of Ni3-V 2 R transgenic rats. All transgenic rats displayed normal kidney histology at postnatal to young age (Fig. 5, C and D) , whereas beyond the third month, probably due to cellular retention of Ni3-V 2 R-/WT V 2 R-complexes, distal tubule obstruction occurred focally. Later, this process occasionally led to nephron loss. There were no signs of pelvic dilatation, hydronephrosis, or sexual dimorphism throughout. To study the urine-concentrating ability of the Ni3-V 2 R transgenic rats, physiological evaluation in metabolic cages was performed at steady state and after 18 h of water deprivation in 10-wk-old male rats. Compared with WT rats, transgenic rats excreted significantly higher urine volumes at steady state (ϩ97%, P Ͻ 0.05; Fig. 6A ). Water deprivation resulted in a significant reduction of urine flow (Ϫ31%, P Ͻ 0.05) and increase of urine osmolality (845 vs. 1,476 mosmol/kgH 2 O, P Ͻ 0.05) in WT rats, whereas transgenic rats, in contrast, failed to reduce urine flow (Fig. 6A ) and showed no increase in urine osmolality (497 vs. 458 mosmol/kgH 2 O, not significant). Evaluation of steady state urine electrolytes revealed a marked hypercalciuria in Ni3-V 2 R transgenic rats (ϩ137%, P Ͻ 0.05), whereas excretion of sodium and potassium was not altered compared with WT rats (Fig. 6, B-D) . Under water deprivation, WT rats showed no change in sodium excretion, whereas the transgenic rats responded with a marked increase (ϩ103%, P Ͻ 0.05; Fig. 6B ). Thirsting also significantly decreased urinary calcium excretion in WT rats (Ϫ45%, P Ͻ 0.05), whereas transgenic rats displayed a mild, insignificant increase (Fig. 6D) . Analysis of plasma electrolytes revealed no major differences between the two genotypes except for moderately reduced chloride levels in the transgenic rats (Ϫ4%, P Ͻ 0.05; Table 1 ). The functional phenotype, thus, suggests an impaired urine-concentrating ability in the Ni3-V 2 R transgenic rats.
To specify this impairment, we next tested whether the Ni3-V 2 R transgenic effect interferes with the epithelial status of NKCC2 as the major vasopressin-sensitive TAL ion cotransporter. Ni3-V 2 R transgenic kidneys showed reduced levels of NKCC2 RNA (Ϫ66%, P Ͻ 0.05), protein (Ϫ63%, P Ͻ 0.05), and phosphorylation at functionally relevant, NH 2 -terminal phosphoacceptor sites (T96 and T101; Ϫ38%, P Ͻ 0.05) compared with WT controls, suggesting decreased activity of NKCC2 (Fig. 7, A-C) . Along the same line, electron microscopic evaluation of the NKCC2 immunoreactive status confirmed a decreased abundance of NKCC2 in transgenic TAL cells as visualized by immunogold grains (Ϫ30%, P Ͻ 0.05; Fig. 8, A-C) . Surface expression of the transporter was also significantly reduced in transgenic TAL (Ϫ41%, P Ͻ 0.05), since 54% of the total of immunogold grains was associated to the luminal membrane of WT TAL, whereas only 32% were found in transgenic TAL (Fig. 8, A, B, D) . In contrast to NKCC2, the abundance and phosphorylation of AQP2 at functionally relevant S256 were not altered in Ni3-V 2 R transgenic rats, suggesting that the transgenic effect was specific for TAL (Fig. 7, A and B) . We next compared expression of COX-2 in macula densa cells of control and Ni3-V 2 R transgenic rats to obtain an estimate for a potential difference in the NaCl load reaching the macula densa (38) . Semiquantitative evaluation of COX-2-positive cells normalized to the number of glomeruli revealed substantially lower values in Ni3-V 2 R compared with WT rats (Ϫ90%, P Ͻ 0.05; Fig. 9, A-C) , suggesting an increased NaCl load at the macula densa due to insufficient reabsorption in the preceding TAL segment. In line with this, creatinine clearance was also reduced in the Ni3-V 2 R rats (Ϫ53%, P Ͻ 0.05; Fig. 9D ).
To study the response of Ni3-V 2 R transgenic TAL to V 2 R stimulation, we have compared the effect of a supraphysiological dose of the V 2 R agonist, dDAVP (1 g/kg body wt for 30 min), on NKCC2 phosphorylation between WT and Ni3-V 2 R transgenic rats. dDAVP induced an expectedly substantial increase of NKCC2 phosphorylation in WT rats (ϩ275%, P Ͻ 0.05; Fig. 10, A and C) , whereas transgenic rats responded to dDAVP only with a minor, statistically insignificant increase of NKCC2 phosphorylation (Fig. 10, B and D) . Thus, these data suggest that reduced V 2 R signaling in TAL results in a substantially lower baseline NKCC2 activity and a blunted response to AVP in the activation of the transporter.
DISCUSSION
The present data have corroborated the functional significance of AVP in the regulation of NaCl reabsorptive transport by the thick ascending limb. Among other endocrine stimuli, AVP has earlier been shown to adjust NKCC2 surface expression and function (10, 15, 21, 24, 33, 46) . In the current understanding, AVP binds to V 2 R in medullary and cortical TAL portions to raise intracellular cAMP via stimulatory G-protein and adenylyl cyclase activation. At least two independent downstream kinase pathways have been identified for short-term or sustained activation of NKCC2. One targets conserved NH 2 -terminal threonine residues of NKCC2 (Thr-96, Thr-101, and Thr-114), involving the interaction of with no lysine kinases (WNK) isoforms with the homologous Ste20-related kinases, oxidative stress-responsive kinase 1 (OSR1) and STE20/SPS1-related Pro/Ala-rich kinase (SPAK) (10, 30, 41, 46) . The other probably relies on cAMP binding to the regulatory subunits of PKA, promoting the action of its catalytic subunits to target AMPK, interacting vesicle-associated membrane protein 2 (VAMP2), or annexin A2, all of which are related with NKCC2's trafficking, surface expression, and inclusion in membrane microdomains (11, 15, 19, 22, 34, 41, 53) . The present reevaluation of V 2 R distribution in the distal nephron sheds new light on local AVP signaling. In spite of a few reports on the absence of V 2 R expression in the distal nephron (18) , there is now compelling evidence that the TAL substantially expresses V 2 R in parallel to CNT/CCD principal cells in various species, including humans, as shown by various technical approaches (33, 35, 37, 47 ). Yet, satisfactory and reliable information on the cellular localization of V 2 R along the tubular epithelial segments was still scarce. In a previous study, we had localized V 2 R mRNA to medullary and cortical TAL, macula densa, DCT, principal cells of CNT and CD, and a subset of type A intercalated cells using high-resolution in situ hybridization. TAL signal was quite significant and more markedly expressed especially in medullary TAL, than in cortical TAL or CNT/CD principal cells. The antibody we had used then in parallel, mostly colocalized with the mRNA signal and expectedly recognized a 50-kDa band in Western blot analysis, but its epithelial signal was weak and predominantly luminal, which is at variance with the established concept of AVP acting from the blood side (24, 33, 47) . Although functional data on luminal V 2 R effects in the collecting duct are available (35), we preferred to reevaluate V 2 R distribution using our newly generated anti-V 2 R peptide antibody. type A intercalated cells are also at variance with the absence of V 2 R signal at this site (32) . The presence of V 2 R mRNA in macula densa may still be considered realistic, since crosshybridization with AVP V 1a and oxytocin receptors, which are partly homologous to and coexpressed with V 2 R, was unlikely owing to careful selection of specific riboprobes (1, 33, 36, 37) . Absence of V 2 R immunoreactivity in macula densa cells may, therefore, be related with differentially regulated protein translation or stability. From the physiological perspective, a reduced V 2 R-mediated effect on macula densa cAMP levels could serve to maintain NKCC2 activity unaffected by the AVP status to provide optimal sensing of the luminal chloride concentration at this site (48, 51) . V 2 R immunostaining in the human TAL was of equal strength as in rodents, although the role of V 2 R-mediated, adenylyl cyclase-dependent AVP signaling in human TAL in the context of urine concentration has been questioned earlier on the basis of functional comparison with rodent data. A less pronounced need to concentrate human urine was considered to reflect a weaker responsiveness of human TAL to AVP (13, 26, 42) . NaCl reabsorption along the TAL chiefly relies on the activity of NKCC2. A wide range of animal models, including normal and genetically engineered mice, AVP-deficient Brattleboro rats, isolated tubule preparations, and cultured cell systems has served to demonstrate that its biosynthesis, surface expression, and phosphorylation are regulated by AVP (16, 21, 33, 46) . In agreement with V 2 R cellular distribution, NaCl transport or transport-equivalent parameters were markedly enhanced upon AVP administration in an adenylate cyclase/ cAMP-dependent manner, with preferentially pronounced effects in medullary TAL (13, 21, 24, 25, 46) , although previous own results have highlighted strong NKCC2 activation also in cortical TAL (33) . Along the same line, the action of other cAMP-generating peptide hormones such as calcitonin, parathyroid hormone, glucagon, in part, synergistically acting with adrenal glucocorticoids, has been established (2, 20, 22) . Regarding the pronounced effects of AVP on TAL parameters, the hypothesis that functions of the urine-concentrating mechanism are determined by V 2 R-dependent signaling along TAL still awaited confirmation. A suitable animal model had been unavailable to demonstrate the selective impact of AVP-V 2 R signaling in TAL, since previous models only provided simultaneous V 2 R deficiency in distal nephron and collecting duct system (29, 55) .
Applying gene targeting technology, we, therefore, decided to generate the Ni3-V 2 R transgenic rat line with TAL-specific suppression of the V 2 R function as a favorable model to address this question. To this end, we have coupled the THP promoter, whose strong activity along medullary and cortical TAL epithelium is established, to an NH 2 -terminal truncated fragment of V 2 R previously identified as a nonsense mutation of V 2 R (Glu242stop), causing X-linked NDI in humans (57) . Among several V 2 R truncation mutants tested previously, the Ni3 fragment strongly impaired the function of the WT, fulllength V 2 R when coexpressed in cell culture; pronounced reductions in maximum cell surface (57) . The presence of Ni3 fragments, which were largely retained intracellularly, obviously caused retention of the WT receptor, probably via the formation of heterodimers with the mutant receptor (57) . In line with a dominant-negative effect of the fragments, the Ni3-V 2 R transgenic rats displayed strongly reduced basolateral surface expression of the fulllength receptor in TAL as detected by immuno-electron microscopy. This suggested a markedly diminished cellular sensitivity for AVP to activate NKCC2. In fact, at steady state condition, NKCC2 biosynthesis, luminal surface expression, and phosphorylation status of the cotransporter in Ni3-V 2 R transgenic rats were reduced to comparable extent as in AVPdeficient Brattleboro rats (33) , but in contrast to the latter, the administration of a supraphysiological dose of AVP failed to activate NKCC2 adequately. These results are partially inconsistent with a previous report of unchanged NKCC2 abundance and surface expression in V 2 R promoter-driven Ni3-V 2 R transgenic mice (55) . However, in Ni3-V 2 R rats, expression was driven by the THP promoter with substantially stronger promoter activity compared with the V 2 R promoter. Therefore, higher cellular abundance of the dominant-negative receptor may be responsible for the stronger TAL phenotype in the Ni3-V 2 R rats compared with the respective mouse model.
Functional evaluation of Ni3-V 2 R rats further confirmed their lack of AVP sensitivity at the TAL level and demonstrated the general contribution of V 2 R signaling in TAL at steady state and when animals were subjected to the challenge of water deprivation. At steady state, Ni3-V 2 R rats revealed significant water loss. Naturally, the phenotype of Ni3-V 2 R transgenic rats was milder compared with other animal models such as Brattleboro rats or mice with global V 2 R deficiency, displaying heavy water losses, since only the TAL was dysfunctional in Ni3-V 2 R rats, whereas principal cells of the connecting tubule and collecting duct were unaffected. Unchanged AQP2 and phospho-AQP2 levels in transgenic kidneys further corroborated the assumption that water reabsorption in collecting duct principal cells was not impaired in this model. A twofold increase in baseline urine flow mirrored insufficient urine concentration, and during antidiuresis, urine flow did not decrease; rather, there was a massive sodium loss, which indicates that in contrast to WT rats, Ni3-V 2 R rats were unable to normalize their urine flow under this condition. Urine osmolality values were in line with this default. The observed mild hypochloremia suggests a low-grade metabolic alkalosis (49, 50) . Considering the causes that underlie the steady-state renal performance, mild Bartter syndrome or furosemide phenotypes best characterize Ni3-V 2 R rats, although in contrast to those, macula densa-dependent signaling was likely intact regarding the absence of THP and V 2 R at this site (3, 4) . With insufficient solute reabsorption along the TAL, activation of the tubuloglomerular feedback (TGF) may reduce GFR in Ni3-V 2 R rats, eventually increase proximal reabsorption, and also stimulate late distal reabsorption, which together would explain the compensated sodium excretion at steady state. In line with activated TGF, macula densa COX-2 levels were strongly reduced in Ni3-V 2 R rats along with diminished creatinine clearance (12, 38) . During antidiuresis, this adaptive scenario obviously failed, causing sodium losses in the Ni3-V 2 R rats. The observed, significant hypercalciuria was in line with the Bartter/furosemide phenotype as well (28, 49, 50) . With roughly 25% of the filtered calcium reabsorbed in the TAL, a failing NKCC2 performance abolishes the transepithelial potential and, thus, the driving force for paracellular Ca 2ϩ passage (7, 17, 23, 40) . Consequently, it is noteworthy that impairing AVP signaling in Ni3-V 2 R rats displays these TALbased defects, which obviously cannot be replaced by the other cAMP-generating hormones mentioned. Considering the potential V 2 R-induced activation of the TAL in human disease, our data may, furthermore, have clinical implications for the treatment of the different forms of NDI (8) .
In summary, the important question as to what extent the loss of functional V 2 R affects TAL function has been answered by these data, which demonstrate significant deficits in urine concentration and ion homeostasis in Ni3-V 2 R rats. Their phenotype resembles that of mild Bartter type 1 syndrome or chronic furosemide treatment, but likely with a functioning TGF to compensate extreme fluid and electrolyte losses. Our data have demonstrated that V 2 R, expressed along the TAL, substantially determines fluid and electrolyte handling by the rodent kidney. 
